ClinicalTrials.gg
Active, not recruitingNCT06027788EMPROUpdated Oct 2, 2026

CTSN Embolic Protection Trial

An interventional study of CardioGard Embolic Protection Cannula and Standard Aortic Cannula in Delirium, Ischemic Stroke and Acute Kidney Injury, sponsored by Icahn School of Medicine at Mount Sinai. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention

How we know

Updated Oct 2, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
842
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Delirium with a site in United States — 37 open to participants now, 60 under way, 7 of them phase 3. Delirium · United States.

Planned enrollment
15th of 194
842 · median 84
Started
2023
with 13 others
No phase
105 of 263
20 open now
Primary completion
2027-04
later than 31 of 59 live
Registered
225th of 263
by date

Among the 263 studies in Delirium with a site in United States, this one is the 15th largest by planned enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2023, is one of 105 with no phase, reaches primary completion later than 31 of the 59 other live ones, and was the 225th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

37 of the 263 studies in Delirium with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Delirium with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Read the detailed description

This is a prospective, multicenter, randomized controlled clinical trial that will evaluate the effectiveness and safety of the CardioGard embolic protection cannula compared to a standard cannula. The enrollment period is expected to last 30 months, and all patients will be followed for 12 months post procedure.

RANDOMIZATION Patients will be randomized 1:1 to the embolic protection device or to a standard cannula in the operating room (OR) immediately after sternotomy and confirmation by the surgical team of the patient's suitability for the proposed intervention (CardioGard embolic protection device). Randomization will be with equal allocation and stratified by site and by procedure (i.e., isolated valve surgery or combined procedures, such as double valve or valve plus coronary artery bypass grafting, CABG). The randomization assignment will be controlled centrally and performed through a web-based data collection system that automates the delivery of the randomization codes. From the point of treatment assignment, primary efficacy will be analyzed by intention-to-treat; that is, the patients will be grouped by their assignments at randomization regardless of whether or not they actually received the treatment to which they were assigned.

STUDY POPULATION The patient population for this trial consists of patients age ≥ 60 undergoing different types of valve surgery with or without CABG via full or minimal-access sternotomy using legally marketed valve(s). Specific inclusion and exclusion criteria are listed below. All patients who meet the eligibility criteria may be included in the study regardless of gender, race, or ethnicity.

SUBSTUDY Sleep Disturbance Ancillary Sub-Study - Patients undergoing surgery for valvular heart disease (VHD) are at high risk for adverse events, including high rates of post-operative delirium (POD). Should circadian disruption be found to be an important predictor in this high-risk population, safe, low cost, and easy to administer therapies to regulate circadian rhythm such as light therapy could be evaluated in future studies

The aims of this ancillary sub-study include:

  1. To investigate the association between short sleep duration, less sleep regularity, and greater circadian rhythm disruption prior to surgery and POD within 7 days of VHD surgery.
  2. To investigate the association between short sleep duration, less sleep regularity and greater circadian rhythm disruption (reduced melatonin and cortisol amplitudes) after surgery and POD within 7 days of VHD surgery.

Approximately 300 EMPRO trial participants will be enrolled into the ancillary study. The study is being conducted in highly experienced clinical centers in the U.S. and Canada. The estimated enrollment period is 12-15 months.

All eligible and consented patients in the parent EMPRO trial will be offered enrollment in this ancillary study through the parent trial consent process.

03

Conditions studied

  • Delirium
  • Ischemic Stroke
  • Acute Kidney Injury
  • Heart Valve Disease
  • Coronary Artery Disease

Keywords

  • Embolic Protection
  • Cardiac Surgery
  • CardioGard
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 years
  • Planned de novo or redo:

    • Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
    • Mitral valve replacement (MVR) ± CABG
    • Mitral Valve Repair + CABG,
    • Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
    • Valve sparing aortic root replacement (David procedure)
    • Valve sparing aortic root replacement (David procedure)
  • No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization
  • Ability to provide and comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • History of clinical stroke within 3 months prior to randomization
  • Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
  • Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
  • Active endocarditis at time of randomization with vegetation criteria
  • Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
  • Participation in an interventional (drug or device) trial
  • Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
  • Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
  • Planned concomitant carotid endarterectomy during index surgical procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
842 participants (estimated)

Study arms

  • Active comparator
    CardioGard Embolic Protection Cannula

    In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU).

    Device: CardioGard Embolic Protection Cannula

  • Placebo comparator
    Standard Aortic Cannula

    In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice

    Device: Standard Aortic Cannula

Interventions

  • DeviceCardioGard Embolic Protection Cannula

    The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.

  • DeviceStandard Aortic Cannula

    An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.

06

What researchers measure

Primary outcomes

  1. Number of patients who experience ischemic stroke and Acute Kidney Injury (AKI)

    The combined number of patients who experience clinical ischemic strokes and acute kidney injuries that have occurred within 3 days post-randomization.

    Time frame: within 3 days post-randomization

  2. Number of patients who experience of death and delirium

    The combined number of patients who experience death and delirium by 7 days post-randomization (with a blanking period for delirium of days 1 and 2 post-operatively).

    Time frame: by 7 days post-randomization

Secondary outcomes

  1. Proportion of patients who experience a clinical ischemic stroke

    The proportion of patients who experience a clinical ischemic stroke within 3 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device).

    Time frame: within 3 days post-randomization

  2. Proportion of patients who experience a clinical ischemic stroke

    The proportion of patients who experience a clinical ischemic stroke within 7 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device).

    Time frame: within 7 days post-randomization

  3. Number of patients with disabling clinical stroke

    Number of patients with disabling clinical stroke within 3 days post-randomization

    Time frame: within 3 days post-randomization

  4. Number of patients with disabling clinical stroke

    Number of patients with disabling clinical stroke within 7 days post-randomization

    Time frame: within 7 days post-randomization

  5. Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)

    Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments.

    Time frame: within 3 days post-randomization

  6. Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)

    Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments.

    Time frame: within 7 days post-randomization

  7. Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2

    Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at baseline days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3\. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead.

    Time frame: at baseline

  8. Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2

    Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 30 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3\. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead.

    Time frame: at 30 days

  9. Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2

    Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 90 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3\. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead.

    Time frame: at 90 days

  10. Montreal Cognitive Assessment (MoCA) Score

    Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at presurgical baseline. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above was considered normal. Higher values represent a better outcome.

    Time frame: at baseline

  11. Montreal Cognitive Assessment (MoCA) Score

    Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 90 days. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome.

    Time frame: at 90 days

  12. Montreal Cognitive Assessment (MoCA) Score

    Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 12 months. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome.

    Time frame: at 12 months

  13. Oral Trail Making Test - Parts A and B (executive function)

    The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

    Time frame: at baseline

  14. Oral Trail Making Test - Parts A and B (executive function)

    The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

    Time frame: at 90 days post-randomization

  15. Oral Trail Making Test - Parts A and B (executive function)

    The trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.

    Time frame: at 12 months post-randomization

  16. Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)

    The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

    Time frame: baseline

  17. Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)

    The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

    Time frame: at 90 days post-randomization

  18. Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)

    The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome.

    Time frame: at 12 months post-randomization

  19. Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution Test (processing speed)

    The WAIS-R Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test that consist of number-symbol pairs. It requires the examinee to copy, into spaces below rows of numbers, the symbols that are paired to each number. The DSST score is the number of digits coded correctly in a 90-second test period

    Time frame: at baseline

  20. Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)

    The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

    Time frame: at baseline

  21. Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)

    The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

    Time frame: at 90 days post-randomization

  22. Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)

    The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts.

    Time frame: at 12 months post-randomization

  23. Incidence of Delirium

    The incidence of delirium will be assessed daily by the Confusion Assessment Method (3D-CAM or CAM-ICU) scale, or by the presence of a delirium adverse event, during the first 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4 and involves the presence/absence of delirium, but not its severity. Any error or behavioral observation consistent with a delirium feature means that feature is present.

    Time frame: first 7 days post-randomization

  24. Duration of Delirium

    The duration of delirium will be measured as the number of days with positive CAM assessments or delirium adverse events by 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4.

    Time frame: first 7 days post-randomization

  25. Severity of Delirium

    The severity of delirium will be measured during daily screening using standardized algorithms for extracting symptom severity from the 3D-CAM and CAM-ICU.

    Time frame: first 7 days post-randomization

  26. Number of Patients who experience Acute kidney injury (AKI)

    Number of Patients who experience Acute kidney injury will be assessed within 7 days post-randomization.

    Time frame: within -7 days post-randomization

  27. All-cause mortality

    All-cause mortality within 90 days post-randomization will be assessed.

    Time frame: within 90 days post-randomization

  28. All-cause mortality

    All-cause mortality within 12-months post-randomization will be assessed.

    Time frame: within 12 months post-randomization

  29. Length of Index Hospitalization

    Overall length of stay for the index hospitalization post-randomization will be measured and broken down by days spent in the ICU versus days not in the ICU.

    Time frame: at hospital discharge, up to 30 days

  30. Discharge disposition

    Discharge disposition

    Time frame: at hospital discharge, up to 30 days

  31. Readmissions rates

    Readmission rates will be calculated for the first 90 days following randomization. Hospitalizations will be classified for all causes including for cardiovascular readmissions.

    Time frame: first 90 days

  32. Readmissions rates

    Readmission rates will be calculated for the duration of follow-up, out to 1 year. Hospitalizations will be classified for all causes including for cardiovascular readmissions.

    Time frame: up to 1 year post-randomization

  33. Days Alive out of Hospital

    Days alive out of hospital and nursing/rehab facilities within 90 days after randomization

    Time frame: within 90 days post-randomization

  34. Actigraphy

    Actigraphy data will be collected for a period of 7 days prior to the index surgical procedure. Actigraphic monitoring employs an accelerometer the size of a watch, which each study patient will wear on the wrist. Collected for participants in substudy.

    Time frame: 7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge

  35. Amount of Circadian Light

    A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to monitor the total amount of circadian light received by the patient. Collected for participants in substudy.

    Time frame: 7-day period prior to index surgical procedure

  36. Photopic Light Levels

    A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate photopic light levels Collected for participants in substudy.

    Time frame: 7-day period prior to index surgical procedure

  37. Circadian Stimulus Values

    A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate circadian stimulus values, Collected for participants in substudy.

    Time frame: 7-day period prior to index surgical procedure

  38. Richards-Campbell Sleep Questionnaire

    Patients who are able to do so will be asked to fill out the Richards-Campbell Sleep Questionnaire (RCSQ), which is a brief 2-minute questionnaire designed for patient use in the ICU. Full score range from 0-100, with higher score indicating better sleep. Collected for participants in substudy.

    Time frame: Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.

Access criteria: Anyone who wishes to access the data. Any purpose. Data are available indefinitely at (Link to be included in the URL field below).

Data sharing details ↗ · biolincc.nhlbi.nih.gov

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Apr 2027, 42 months after the start.

Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 42 months is above that.

Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Sep 7, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Sites
1 site added, 5 sites removed
Show site
  • University of Cincinnati Medical Center · Cincinnati, United States
Show 5 removed
  • Indiana University · Bloomington, United States
  • Indiana Ohio Heart · Fort Wayne, United States
  • New York Presbyterian-Cornell Medical Center · New York, United States
  • NYU Langone Hospital Brooklyn · New York, United States
  • University Hospitals · Cleveland, United States
across 2 updates, Sep 28, 2026 – Oct 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Massachusetts General Hospital · Boston, United StatesContact A•••@mgh.harvard.edu→m•••@mgh.harvard.edu
  • University of Michigan · Ann Arbor, United StatesContact c•••@med.umich.edu→j•••@med.umich.edu
  • Saint Luke's Hospital of Kansas City · Kansas City, United StatesContact r•••@saint-lukes.org→d•••@bjc.org
Sep 28, 2026
Show all 2 updates
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    5 sites removed
    Show 5 removed
    • Indiana University · Bloomington, United States
    • Indiana Ohio Heart · Fort Wayne, United States
    • New York Presbyterian-Cornell Medical Center · New York, United States
    • NYU Langone Hospital Brooklyn · New York, United States
    • University Hospitals · Cleveland, United States
    + 2 other changes: verification date and contact details
  2. Sep 28, 2026
    1 site added
    Show site
    • University of Cincinnati Medical Center · Cincinnati, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Massachusetts General Hospital · Boston, United StatesContact A•••@mgh.harvard.edu→m•••@mgh.harvard.edu
    • University of Michigan · Ann Arbor, United StatesContact c•••@med.umich.edu→j•••@med.umich.edu
    • Saint Luke's Hospital of Kansas City · Kansas City, United StatesContact r•••@saint-lukes.org→d•••@bjc.org
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06027788
Responsible party
Annetine Gelijns (Professor of Health Policy, Chair Department of Health Evidence & Policy, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Sep 7, 2023
Start date
Sep 18, 2023
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Annetine C. Gelijns, PhD
principal investigator · Icahn School of Medicine at Mount Sinai
Steve Messe, MD
principal investigator · University of Pennsylvania
Alexander Iribarne, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion